Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis
Author:
Open Access
- 9 September 2017
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 9 (9) , e1668
Abstract
This study represents the first 10 year analysis of the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of early low-risk prostate cancer. Two hundred and thirty males were treated with Cyberknife SBRT to a dose of 35 Gray (Gy) or 36.25 Gy in five consecutive days. All patients had a Gleason score of six and a PSA < 10ng/ml. Median follow-up is nine years. The median age was 69.5 years and median prostate specific antigen (PSA) was 5.6ng/ml. The treatment was delivered with homogeneous planning with a dose prescription of 82-87% of the maximum dose to cover the planning target volume (PTV). Ten-year biochemical disease free survival was 93% with either dose. Local control was 98.4%. Median prostate specific antigen (PSA) dropped to 0.1 by five years and has remained there. Toxicity was mild with 10% of patients having Grade two-three late urinary toxicity and 4% having the late grade two rectal toxicity. Mean Expanded Prostate Cancer Index Composite (EPIC) Quality of Life (QOL) scores declined initially for bowel and urinary domains, but recovered to baseline, where they remain. EPIC sexual scores have declined by 40%. Stereotactic body radiotherapy to a dose of 35 Gy-36.25 Gy is an effective treatment for early low-risk prostate cancer, with acceptably low toxicity. There appears to be no benefit to increasing the dose beyond 35 Gy. Ten-year biochemical disease free survival appears to be higher than with standard intensity modulated radiotherapy (IMRT).Keywords
This publication has 14 references indexed in Scilit:
- What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalationRadiotherapy and Oncology, 2015
- Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year StudyFrontiers in Oncology, 2014
- Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trialsRadiotherapy and Oncology, 2013
- Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 yearsRadiation Oncology, 2013
- Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experienceRadiation Oncology, 2013
- Stereotactic body radiation therapy for the primary treatment of localized prostate cancerJournal of Radiation Oncology, 2012
- Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) GyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Ten‐year outcomes of high‐dose, intensity‐modulated radiotherapy for localized prostate cancerCancer, 2010
- Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancerUrology, 2000